Endpoints News 2026年1月27日 CMS picks Lilly’s Trulicity, Gilead's Biktarvy for third round of Medicare negotiations
Endpoints News 2025年12月18日 Lilly’s orforglipron is the first oral obesity therapy to show its worth in the maintenance setting
Endpoints News 2025年12月11日 Lilly’s triple agonist posts strongest weight loss data yet, unusual skin side effect also reported